A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease
Phase of Trial: Phase II/III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms AMARANTH
- Sponsors Eli Lilly
- 20 Jul 2018 According to Eli Lilly media release, data from this study will be presented at the Alzheimer's Association International Conference (AAIC).
- 05 Jul 2018 Planned End Date changed from 1 Sep 2019 to 1 Oct 2018.
- 05 Jul 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History